Clinical interference refers to external pressures or restrictions that constrain health professionals' judgment about patient care. These can arise through corporate policies, insurer requirements, clinical trial protocols, or the design and use of clinical software.
The issue concerns the boundary between legitimate oversight and constraints that compromise clinical judgment. Professional autonomy remains subject to clinical evidence, professional standards and patients' choices. Organizational oversight and clinical decision support systems can support care, while commercial incentives and operational requirements can introduce competing pressures.
In a paper published in Annals of Oncology in 2023, a European Society for Medical Oncology panel defined clinical interference in clinical trials as a situation in which a study protocol, or its interpretation by a sponsor or contract research organization, imposes a patient-management decision that conflicts with the investigator's medical judgment. The authors described such disputes as infrequent. They distinguished them from recommendations on treatment toxicities based on centrally collected safety data, decisions to stop enrollment, and advice that leaves the final treatment decision with the investigator.
The expression also appears in dental regulation. Section 466.001 of the Florida Statutes identifies protection of dentists and dental hygienists from "undue clinical interference" by unlicensed persons as one purpose of the state's dental-practice legislation.
Constraints on clinical decisions may operate through protocols, staffing requirements, payment conditions or software controls. Their effect depends on which decision is affected, who sets the requirement and whether the clinician can depart from it in response to a patient's needs. A recommendation that can be declined differs from a requirement enforced through blocked overrides, additional approvals or performance assessments. Restrictions may originate in a software product, its local configuration or an employer's policy.
In a 2026 report, the Federation of State Medical Boards identified premature-discharge requirements, restrictions on referrals, unreasonable patient-volume or time limits, and retaliation for raising safety concerns as examples of inappropriate interference with physicians' decisions. The report also recognized that corporate organization and outside investment can improve infrastructure, coordination and research, while creating potential conflicts between organizational interests and duties to patients.
Appointment lengths, workloads and productivity targets can constrain care when meeting them requires shortened assessments, unsuitable delegation or inadequate supervision. A productivity target alone does not establish inappropriate interference; its effect on patient care and professional judgment is the relevant concern.
Clinical protocols can support safer care, but they may also constrain decisions when departure is prohibited or penalized regardless of an individual patient's circumstances. Such requirements may originate with an employer, management company or health plan.
Clinical decision-support systems use patient information to generate recommendations and reminders, often within electronic health record software. In a 2022 analysis, bioethicist Megan Prictor discussed their benefits alongside the risk that undisclosed commercial interests could influence the advice presented to clinicians.
The extent of clinical oversight depends on the tasks a system performs, when its outputs are reviewed and whether a clinician can reject its recommendations. Review of each output before use differs from retrospective sampling or formal approval without a meaningful opportunity to assess the recommendation.
Automation bias describes excessive reliance on automated decision support that reduces independent checking of information. A systematic review by David Lyell and Enrico Coiera found that this could occur in diagnostic tasks as well as in multitasking environments, particularly when verifying a system's recommendation was cognitively demanding. The authors also noted limitations and inconsistent reporting in the available research.
A randomized clinical-vignette study published in JAMA in 2023 examined how AI predictions affected diagnostic decisions by physicians, nurse practitioners and physician assistants. Standard predictions accompanied by image-based explanations improved accuracy by 4.4 percentage points over baseline, while systematically biased predictions without explanations reduced it by 11.3 percentage points. Explanations did not significantly mitigate the adverse effect of biased predictions. The study assessed responses to clinical vignettes rather than patient outcomes in routine practice.
Prior authorization makes insurance coverage for specified services conditional on advance approval. A 2026 perspective in npj Digital Medicine discussed concerns about AI-assisted coverage denials in Medicare Advantage, including litigation and the burden of authorization requests and appeals. Its authors called for greater transparency in the use of insurer algorithms.
In November 2025, CodeBlue reported that Bank Negara Malaysia had sought explanations from insurers and third-party administrators about alleged interference with clinical decisions, including disputes over diagnostic tests, hospital admissions and treatment choices. The report attributed information about the regulator's requests to an unnamed source and described the conduct as alleged or perceived interference.
In January 2020, electronic health record vendor Practice Fusion agreed to pay US$145 million to resolve criminal and civil investigations. Under a deferred prosecution agreement, it admitted soliciting and receiving payments from an opioid manufacturer in exchange for using its software to influence opioid prescribing. The criminal component involved more than $26 million in fines and forfeiture; the remaining amount concerned civil settlements. Prictor subsequently examined the case as an example of concealed commercial influence in clinical software.
In a lawsuit filed in November 2023, relatives of Medicare Advantage beneficiaries alleged that UnitedHealth Group and naviHealth used the nH Predict tool to displace physicians' assessments and prematurely end coverage for post-acute care. Optum disputed the allegations, describing the system as a care-planning tool and stating that qualified physicians made medical-necessity determinations.
Contractual claims survived a partial dismissal of the lawsuit. On 9 March 2026, a federal court ordered disclosure of records concerning the tool, coverage policies and employee incentives. The order concerned discovery and did not determine whether the alleged misuse of the system had occurred.
In May 2026, California's attorney general announced a proposed settlement with Aspen Dental Management over allegations that it had exceeded its administrative role and unlawfully directed dental practices. The allegations included offering dental hygienists payments for selling clear aligners. The proposed agreement included $2 million in penalties, $300,000 in restitution, and restrictions on corporate control and sales incentives. It remained subject to court approval when announced. Aspen did not admit the factual or legal allegations in the settlement stipulation.
On 13 October 2026, CVS Pharmacy and related entities agreed to pay $315 million to resolve federal allegations concerning unlawful dispensing of opioids and other controlled substances. The United States Department of Justice alleged that performance targets, incentive compensation and staffing policies contributed to invalid prescriptions being filled, and that company policies restricted pharmacists from warning colleagues about problematic prescribers. CVS disputed the claims and admitted no wrongdoing. The settlement included monitoring and reporting requirements, and the Justice Department stated that there had been no determination of liability.
The World Medical Association's Declaration of Seoul identifies clinical independence as physicians' ability to exercise judgment without inappropriate outside influence. It also recognizes patients' rights to decide about treatment, resource constraints, evidence-based standards and legitimate peer review as limits on professional autonomy.
The International Council of Nurses' 2021 code of ethics states that nurses should ensure that technology respects people's safety, dignity and rights. Its provisions on AI and devices call for care to remain centered on the person and for technology to support human relationships rather than replace them.
The Federation of State Medical Boards' 2026 report recommended clearer standards for clinical independence, protection for physicians reporting inappropriate interference, and cooperation between medical boards and other regulators. These were recommendations to be applied within the relevant bodies' legal authority.
California's Senate Bill 1120, enacted in September 2024, established requirements for AI, algorithms and software used in utilization review by covered health plans and insurers. The legislation requires consideration of individual clinical information, prohibits reliance solely on group datasets, and states that such tools must not supplant health-care-provider decision-making. Decisions to deny or modify authorization on grounds of medical necessity are reserved to appropriately qualified licensed professionals.